Aviragen Therapeutics was acquired by Vaxart in 2017 and was focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11.
Company Details
- Employees
- 35
- Founded
- -
- Address
- 2500 Northwinds Parkway,
- Phone
- 678-221-3343
- in****@****ics.com
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- aviragentherapeutics.com
- Keywords
- Anti-infective drug development.
- HQ
- Alpharetta, GA
Aviragen Therapeutics Questions
Aviragen Therapeutics's helpline number is 678-221-3343
Aviragen Therapeutics's website is aviragentherapeutics.com
Aviragen Therapeutics's LinkedIn profile is https://www.linkedin.com/company/aviragen-therapeutics
Aviragen Therapeutics has
35 employees.
View email and phone details for 35
employees at Aviragen Therapeutics.
Aviragen Therapeutics's industry is
Research Services
Aviragen Therapeutics's top competitors are
Alithia Life Sciences,
Inc Research,
Kinoxis Therapeutics Pty Ltd,
Complete Phase,
Clinovo,
Inclin, Inc,
Purecdm,
Grand Pacific Cro,
Chimeric Therapeutics,
Cynata Therapeutics.
Aviragen Therapeutics's support email address is info@aviragentherapeutics.com
Aviragen Therapeutics's categories are Research Services
Aviragen Therapeutics's founding year is 1984
